Total revenues increased by $2,329,000, or 2.7%, to $89,096,000 in the year ended December 31, 2025, from $86,767,000 in 2024. Net income increased by $618,000, or 65.0%, to $1,569,000 in 2025 from $951,000 in 2024. Net income per basic and diluted common share remained $0.01 for both 2025 and 2024. IT segment revenue decreased by $489,000, or 1.1%, to $42,465,000, primarily due to the sale of VasoHealthcare IT (VHC-IT) in November 2025, partially offset by an increase of $932,000 in managed network services revenue. Professional sales service segment commission revenues increased by $2,856,000, or 6.9%, to $44,191,000, driven by a higher blended commission rate and increased GEHC equipment delivery volume. Equipment segment revenue decreased by $38,000, or 1.5%, to $2,440,000, mainly due to a 13.3% decrease in China operations, partially offset by a 35.9% increase in US ARCS-cloud software-as-a-service revenues. Gross profit increased by $2,622,000, or 5.0%, to $54,672,000, with the gross margin improving to 61.4% in 2025 from 60.0% in 2024. Operating loss was $2,891,000 in 2025, a decrease of $3,176,000 from an operating income of $285,000 in 2024, primarily due to a $4,639,000 goodwill impairment charge in the IT segment. Adjusted EBITDA decreased by $2,549,000 to $(1,548,000) in 2025 from $1,001,000 in 2024. The company recorded an income tax benefit of $2,875,000 in 2025, compared to an expense of $326,000 in 2024, primarily due to the release of the remaining deferred tax asset valuation allowance of $3,027,000. Cash and cash equivalents were $35,050,000 at December 31, 2025, up from $26,271,000 in 2024. The GEHC Agreement, a significant revenue source, was extended through December 31, 2030.